One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 31, 100404
Abstract
No abstract availableKeywords
This publication has 244 references indexed in Scilit:
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcomaNature Genetics, 2012
- Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effectorProceedings of the National Academy of Sciences, 2010
- Analysis of Ewing Sarcoma (EWS)-Binding Proteins: Interaction with hnRNP M, U, and RNA-Helicases p68/72 within Protein−RNA ComplexesJournal of Proteome Research, 2009
- A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcomaNature Medicine, 2009
- GLI1 Is a Direct Transcriptional Target of EWS-FLI1 OncoproteinJournal of Biological Chemistry, 2009
- EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiationProceedings of the National Academy of Sciences, 2009
- Microsatellites as EWS/FLI response elements in Ewing's sarcomaProceedings of the National Academy of Sciences, 2008
- Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancerProceedings of the National Academy of Sciences, 2008
- Mesenchymal Stem Cell Features of Ewing TumorsCancer Cell, 2007